| Literature DB >> 32486359 |
Katarzyna Pauter1,2, Małgorzata Szultka-Młyńska1, Bogusław Buszewski1,2.
Abstract
Antibiotics were initially natural substances. However, nowadays, they also include synthetic drugs, which show their activity against bacteria, killing or inhibiting their growth and division. Thanks to these properties, many antibiotics have quickly found practical application in the fight against infectious diseases such as tuberculosis, syphilis, gastrointestinal infections, pneumonia, bronchitis, meningitis and septicemia. Antibiotic resistance is currently a detrimental problem; therefore, in addition to the improvement of antibiotic therapy, attention should also be paid to active metabolites in the body, which may play an important role in exacerbating the existing problem. Taking into account the clinical, cognitive and diagnostic purposes of drug monitoring, it is important to select an appropriate analytical method that meets all the requirements. The detection and identification of the microorganism responsible for the infection is also an essential factor in the implementation of appropriate antibiotic therapy. In recent years, clinical microbiology laboratories have experienced revolutionary changes in the way microorganisms are identified. The MALDI-TOF MS technique may be interesting, especially in some areas where a quick analysis is required, as is the case with clinical microbiology. This method is not targeted, which means that no prior knowledge of the infectious agent is required, since identification is based on a database match.Entities:
Keywords: analytical techniques; antibiotics; biological samples; mass spectrometry; microorganisms
Mesh:
Substances:
Year: 2020 PMID: 32486359 PMCID: PMC7321139 DOI: 10.3390/molecules25112556
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1An overview of main antibiotics.
Figure 2The concept of antibiotics’ metabolism in the liver.
The antibacterial activity of selected antibiotic metabolites.
| Antibiotic | Metabolite | Activity of the Metabolite Compared to Initial Compound | MIC |
| |
|---|---|---|---|---|---|
| A | M | ||||
| Metronidazole (nitroimidazole) | 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole | < | 0.5 | 1.0 | [ |
| Metronidazole (nitroimidazole) | 2-methyl-5-nitroimidazole-1-acetic acid | < | 0.5 | 16.0 | [ |
| Clarithromycin (macrolide) | 14-hydroxyclarithromycin | > | 2.4 | 1.2 | [ |
| Cefotaxime (β-lactam) | desacetylcefotaxime | = | >128 | >128 | [ |
| Fidaxcomicin (macrolide) | OP-1118 | < | 0.008 | 0.25 | [ |
| Tinidazole (nitroimidazole) | hydroxytinidzole | > | 32 | 2 | [ |
| Metronidazole (nitroimidazole) | hydroxymetronidazole | > | 32 | 4 | [ |
| norfloxacin (quinolone) | < | 3.01 | 7.5 | [ | |
| norfloxacin (quinolone) | < | 3.01 | ≥50 | [ | |
| Cefetamet (β-lactam) | cefetamet pivoxil | = | 0.5 | 0.5 | [ |
| Ceftiofur (β-lactam) | desfuroylceftiofur | < | 1.0 | 2.0 | [ |
A, antibiotic; M, metabolite; <, the metabolite indicates lower antimicrobial activity than the parent compound; >, the metabolite indicates higher antimicrobial activity than the parent compound; =, the metabolite indicates comparable antimicrobial activity to the parent compound.
Figure 3Molecular mechanism of antimicrobial resistance.
Figure 4The analytical techniques for determination of antibiotics.
Identification and determination of antibiotics and their metabolites by the liquid chromatography technique.
| Antibiotic/Metabolite | Matrix | Sample Preparation | Detection | Conditions | LOD/LOQ | Ref. |
|---|---|---|---|---|---|---|
| ceftriaxone | human plasma | protein precipitation (ACN) | HPLC-MS/MS | Column: Polaris 5 C18-A (150 mm × 3.0 mm i.d., 3.0 µm) | -/0.4–300 µg/mL (ceftriaxone) | [ |
| ceftriaxone | human plasma | protein precipitation (MeOH) | LC-MS/MS | Column: Agilent Zorbax Eclipse Plus C18 (100 mm × 2.1 mm i.d., 3.5 μm) | -/1.01–200 µg/mL | [ |
| amoxicillin | urine | Filtration (0.45 µm) | LC-UV | Column: Zorbax C18 (150 mm × 4.6 mm i.d., 5.0 µm) | 1.5–15/50 ng/mL | [ |
| amoxicillin | human plasma | protein precipitation (ACN) | UPLC-MS/MS | Column: Waters Acquity UPLC BEH C18 (100 mm × 2.1 mm i.d., 1.7 µm) | -/1.0–100 mg/L | [ |
| cefazolin | human plasma | protein precipitation (ACN) | UHPLC-MS/MS | Column: Phenomenex Kinetex C8 (50 mm × 2.1 i.d., 1.7 μm) | 0.04–0.05/1 µg/mL | [ |
| clarithromycin | human serum | LLE | HPLC-FD | Column: Shimpack CLC-ODS (150 mm × 4.6 mm i.d., 5 µm) | 0.01/0.025 µg/mL | [ |
| metronidazole | human plasma | LLE | HPLC-UV | Column: Eclipse XDB-phenyl (250 mm × 4.6 mm i.d., 5 µm) | -/0.05–30 µg/mL | [ |
| metronidazole | human feces | LLE | LC-MS/MS | Column: Waters Acquity UPLC BEH C18 (50 mm × 2.1 mm i.d., 1.7 µm) | 5/66 ng/mL | [ |
| levornidazole | human feces | LLE | HPLC-MS/MS | Column: Atlantis T3 columns (150 mm × 2.1 mm i.d., 5.0 µm) | -/0.005–2.0 µg/mL | [ |
| cefepime | human serum | protein precipitation | HPLC-MS/MS | Column: Fortis C8 (100 mm × 2.1 mm i.d., 3 µm) | -/0.25–200 mg/L | [ |
| cycloserine | human plasma | SPE | HPLC-PDA | Column: Allantis T3 (150 mm × 4.6 mm id, 3 µm) | 0.3/1.2 µg/mL | [ |
| linezolid | human serum | dilution (acetate buffer, pH 3.5) | HPLC-UV | Column: Nucleosil-100 5C18 (125 mm × 4 mm id, 5 µm) | 0.07/0.14 mg/L | [ |
| fosfomycin | human plasma | protein precipitation (ACN) | LC-MS/MS | Column: Merck SeQuant zic-HILIC (50 mm × 2.1 mm i.d., 5 µm) | 0.01/1.02 µg/mL | [ |
| amoxicillin | plasma | protein precipitation (ACN) | HPLC-PDA | Column: Inertsil ODS-3 (250 mm × 4.0 mm i.d., 5 µm) | 3.3–6.6/10–20 ng/mL | [ |
| amoxicillin | whole blood | SPME | HPLC-QqQ-MS | Column: Phenomex GRACE C18 (50 mm × 2.0 mm i.d., 4 µm) | 0.031/0.093 µg/mL | [ |
|
| plasma | ultrafiltration | UHPLC-MS/MS | Column: C18 Shimadzu Shim-pack XR-ODS III (50 × 2.0 mm i.d, 1.6 μm) | 0.01/0.5 µg/mL | [ |
|
| human plasma | protein precipitation (ACN) | UPLC-MS/MS | Column: ACQUITY UPLC BEH C18 column (100 mm × 2.1 mm i.d. 1.6 μm) | -/0.5–1.5 mg/L | [ |
|
| human | protein precipitation (ACN) | UHPLC-UV | Column: Hypersil Gold PFP column (100 mm × 2.1 mm i.d. 1.9 μm) | -/2–100 mg/L | [ |
ACN, acetonitrile; DCM, dichloromethane; FMOC-Cl, 9-fluorenylmethyl chloroformate; LLE, liquid-liquid extraction; SDS, sodium dodecyl sulfate; SPE, solid-phase extraction; TFA, trifluoroacetic acid; SPME, solid-phase microextraction; Q1, parent ion; Q3, product ion; Ex, Excitation wavelength; Em, Emission wavelength.
Figure 5A comparison of the separation analysis by high performance liquid chromatography (HPLC) and capillary electrophoresis (CE).
Identification and determination of antibiotics and their metabolites by electrophoretic method.
| Antibiotic/Metabolite | Matrix | Sample Peparation | Detection | Capillary Parameters | LOD/LOQ | Ref. |
|---|---|---|---|---|---|---|
| cefazolin | serum | lyophilization | CZE-PD | 25 mM borate buffer (pH 9.1), 50 mM SDS | 0.42–0.84/ µg/mL | [ |
| sulfamethoxazole | human serum | protein precipitation (ACN) | MEKC-DAD | 20 mM borate buffer (pH 9.3), 25 mM SDS + 5% ACN | 0.04–0.06/0.13–0.24 mg/L | [ |
| ceftazidime | wound drainage | filtration | CZE-UV | 25 mM borate, buffer (pH 9.2) | 0.21–0.48/ µg/mL | [ |
| ceftazidime | human blood | protein precipitation (ACN) | CE-DAD | 50 mM chloroacetic acid, 20% | 0.42/ µg/mL | [ |
| vancomycin | human serum | direct injection | MEKC-PDA | 25 mM borate buffer (pH 10.0), 100 mM SDS | 1 µg/mL | [ |
| daunorubicin | human plasma | SPE | CE-LIF | 100 mM sodium dihydrogenphosphate (pH 5.0) | -/1 µg/L | [ |
| cephalexi | urine | filtration | CZE-DAD | 50 mM citrate buffer (pH 6) | 2.5–5/ µg/mL | [ |
| cefadroxil | urine | filtration | CE-UV | 50 mM sodium tetraborate buffer (pH 9.0) | 0.5–5/-µg mL | [ |
| moxifloxacin | human blood | protein precipitation (MeOH) | CE-FD | 50 mM phosphoric acid (pH 7.55), 40% acetonitrile | 0.5–15/1.5–45 µg/L | [ |
| gentamicin | smear of the wound | direct injection | CZE-DAD | TBE buffer, 0.0125% PEO (pH 8.53) | -/- | [ |
Figure 6The popular methods to microorganism identification.
Figure 7Differences between Gram-negative (a) and Gram-positive (b) of bacteria cell wall.
Figure 8Schematic illustration of MALDI-TOF MS (matrix-assisted laser desorption/ionization with time of flight) analysis.
Data of bacterial isolates from various clinical materials determination by MALDI-TOF MS.
| Bacteria Speices | Clinical Samples | Matrix Solution | Sampling Technique | Identification System | Degree of Compliance Identification (%) | Ref. |
|---|---|---|---|---|---|---|
| urine | HCCA | direct application | MALDI VITEK® MS | 86 | [ | |
|
| urine | HCCA | protein extraction | MALDI BioTyper | 95 | [ |
|
| blood | HCCA | direct application | MALDI VITEK® MS | 65 | [ |
|
| saliva | HCCA | protein extraction | MALDI BioTyper | 80 | [ |
|
| blood | HCCA | protein extraction | MALDI BioTyper | 99 | [ |
|
| sputum | HCCA | protein extraction | MALDI BioTyper | 97 | [ |
| abdomen fluid | HCCA | direct application | MALDI BioTyper | 100 | [ | |
|
| blood | HCCA | protein extraction | MALDI BioTyper | 100 | [ |
| feces | HCCA | direct application | MALDI BioTyper | 100 | [ | |
| vitreous samples | HCCA | protein extraction | MALDI BioTyper | 96 | [ | |
|
| urine | HCCA | direct application | MALDI BioTyper | 94 | [ |
|
| blood | - | direct application | MALDI BioTyper | 94 | [ |